- Home
- OLMA vs ALVO Comparison
OLMA vs ALVO Comparison
Compare OLMA & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLMA | ALVO |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.9M | 1.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OLMA | ALVO |
|---|---|---|
| Price | $11.57 | $3.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $44.89 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 680.3K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.47 | $2.94 |
| 52 Week High | $36.26 | $9.25 |
Technical Indicators
Market Signals| Indicator | OLMA | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 54.13 |
| Support Level | $7.79 | $3.11 |
| Resistance Level | $13.09 | $3.65 |
| Average True Range (ATR) | 0.64 | 0.19 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 26.37 | 85.96 |
Price Performance
Historical ComparisonAbout OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.